231 related articles for article (PubMed ID: 22719966)
1. Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1.
Nischang M; Sutmuller R; Gers-Huber G; Audigé A; Li D; Rochat MA; Baenziger S; Hofer U; Schlaepfer E; Regenass S; Amssoms K; Stoops B; Van Cauwenberge A; Boden D; Kraus G; Speck RF
PLoS One; 2012; 7(6):e38853. PubMed ID: 22719966
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy.
Araínga M; Edagwa B; Mosley RL; Poluektova LY; Gorantla S; Gendelman HE
Retrovirology; 2017 Mar; 14(1):17. PubMed ID: 28279181
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
Miti S; Handema R; Mulenga L; Mwansa JK; Abrams E; Frimpong C; Burke VM; Zulu M; Siwingwa M; Mwakazanga D; Kalibala S; Denison JA
PLoS One; 2020; 15(8):e0236156. PubMed ID: 32804970
[TBL] [Abstract][Full Text] [Related]
5. HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.
Satheesan S; Li H; Burnett JC; Takahashi M; Li S; Wu SX; Synold TW; Rossi JJ; Zhou J
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343582
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
[TBL] [Abstract][Full Text] [Related]
8. Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China.
Gu L; Han Y; Li Y; Zhu T; Song X; Huang Y; Yang F; Guan S; Xie J; Gohda J; Hosoya N; Kawana-Tachikawa A; Liu W; Gao GF; Iwamoto A; Li T; Ishida T
PLoS One; 2015; 10(8):e0134539. PubMed ID: 26288093
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
Takou D; Fokam J; Teto G; Santoro MM; Ceccherini-Silberstein F; Nanfack AJ; Sosso SM; Dambaya B; Salpini R; Billong SC; Gori C; Fokunang CN; Cappelli G; Colizzi V; Perno CF; Ndjolo A
BMC Infect Dis; 2019 Mar; 19(1):246. PubMed ID: 30871487
[TBL] [Abstract][Full Text] [Related]
10. Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis.
Campos N; Myburgh R; Garcel A; Vautrin A; Lapasset L; Nadal ES; Mahuteau-Betzer F; Najman R; Fornarelli P; Tantale K; Basyuk E; Séveno M; Venables JP; Pau B; Bertrand E; Wainberg MA; Speck RF; Scherrer D; Tazi J
Retrovirology; 2015 Apr; 12():30. PubMed ID: 25889234
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Sturt AS; Dokubo EK; Sint TT
Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
[TBL] [Abstract][Full Text] [Related]
12. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
13. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T
Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
[TBL] [Abstract][Full Text] [Related]
14. Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China.
Chen J; Zhang M; Shang M; Yang W; Wang Z; Shang H
BMC Infect Dis; 2018 Nov; 18(1):571. PubMed ID: 30442114
[TBL] [Abstract][Full Text] [Related]
15. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
Domingo P; Ribera E
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
[TBL] [Abstract][Full Text] [Related]
16. Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.
Svicher V; Alteri C; Artese A; Forbici F; Santoro MM; Schols D; Van Laethem K; Alcaro S; Costa G; Tommasi C; Zaccarelli M; Narciso P; Antinori A; Ceccherini-Silberstein F; Balzarini J; Perno CF
J Acquir Immune Defic Syndr; 2010 Nov; 55(3):336-44. PubMed ID: 20739898
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group.
Neumann AU; Tubiana R; Calvez V; Robert C; Li TS; Agut H; Autran B; Katlama C
AIDS; 1999 Apr; 13(6):677-83. PubMed ID: 10397562
[TBL] [Abstract][Full Text] [Related]
18. An advanced BLT-humanized mouse model for extended HIV-1 cure studies.
Lavender KJ; Pace C; Sutter K; Messer RJ; Pouncey DL; Cummins NW; Natesampillai S; Zheng J; Goldsmith J; Widera M; Van Dis ES; Phillips K; Race B; Dittmer U; Kukolj G; Hasenkrug KJ
AIDS; 2018 Jan; 32(1):1-10. PubMed ID: 29112072
[TBL] [Abstract][Full Text] [Related]
19. Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling.
Maggiolo F; Callegaro A; Arici C; Quinzan G; Gregis G; Ripamonti D; Tebaldi A; Goglio A; Suter F
Antivir Ther; 2003 Apr; 8(2):121-6. PubMed ID: 12741624
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
